Avadel Pharmaceuticals plc
http://www.avadel.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avadel Pharmaceuticals plc
Relay’s SHP2 Runs Aground As Roche Pulls Out Of Development Deal
Relay said in an SEC filing that Roche terminated the deal to develop migoprotafib, though Roche emphasized that it was not due to any emerging clinical safety concerns.
Revolution Medicine Gets Set For Phase III After Pancreatic Cancer Results
The company could be first to bring a multi-RAS inhibitor to market, and has NSCLC as well as pancreatic cancer in its sights.
Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan
Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.
Erasca Revamps With Two In-Licensings, $160m Follow-On Offering
The San Diego biotech is also de-emphasizing three ongoing targeted cancer therapy candidates and giving itself the flexibility to focus on RAS- or KRAS-targeting approaches.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Vaccines
-
Drug Delivery
- Controlled Release
- Macromolecule
- Other Names / Subsidiaries
-
- Avadel Specialty Pharmaceuticals, LLC
- Éclat Pharmaceuticals, L.L.C.
- FSC Pediatrics, Inc.
- FSC Therapeutics, LLC
- FSC Laboratories, Inc.
- FSC Holdings, LLC
- Flamel Technologies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice